If You Invested in Ramm Pharma (RAMMF)

RAMM Pharma Corp. (CSE: RAMM; OTC: RAMMF) is active in the field of cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other hemp- and cannabis-based products. According to multiple company disclosures, RAMM has built a diversified international production and sales platform that combines pharmaceutical operations in Latin America with vertically integrated hemp and cannabis activities in Europe.

Core business and pharmaceutical focus

RAMM describes itself as a leader in plant-derived cannabinoid pharmaceutical products. The company operates an established pharmaceutical and medical product business in Uruguay, where it has developed several medically registered and approved plant-derived cannabinoid pharmaceutical products. These products have been authorized for sale and/or compassionate use in several Latin American countries, as noted in company news releases.

RAMM also reports a pipeline of new products in various stages of approval and development. Disclosures reference registered cannabis-based and hemp-based nutrition products and specialized veterinary products, which are produced at a good-manufacturing-practice (GMP) certified formulation facility in Montevideo, Uruguay. The company further states that it operates pharmaceutical, cosmetic and nutraceutical product development and medical services activities serving the local market.

Veterinary cannabinoid products

Within animal health, RAMM has highlighted NettaVet™ 10% CBD Formulation, a veterinarian pharmaceutical formulation of highly purified, plant-derived cannabidiol. The company reports that the Uruguayan Ministry of Agriculture, Livestock and Fisheries, through its Veterinary Laboratories Division (DILAVE), approved and registered NettaVet™ 10% as a veterinary pharmaceutical product. RAMM states that NettaVet™ 10% is the first CBD veterinary medicine to obtain a federal registration as a pharmaceutical product, and that production and commercial sales of this formulation can commence under that approval.

NettaVet™ CBD veterinary products have been under development by NettaLife, a wholly owned subsidiary dedicated to the production, export and commercialization of pet products, food, pharmaceutical and cosmetic products aimed at animal health and wellness. Company communications indicate that additional NettaVet™ formulations and clinical trials are in progress, but those details are presented as forward-looking information.

European operations and vertical integration

RAMM’s disclosures emphasize a European platform built primarily through its ownership of Canapar Corp. and HemPoland. Through Canapar, which is based in Italy, RAMM describes itself as well positioned to become one of Europe’s vertically integrated cannabis companies. Company news releases state that Canapar operates a state-of-the-art extraction facility in Sicily that is designed to meet European Union Good Manufacturing Practice (EU-GMP) and Italian Medicine Agency (AIFA) standards. RAMM reports that this pharma-grade facility is the largest extraction facility of its type in Europe and is designed to process hemp biomass into cannabidiol (CBD) and other active compounds for pharmaceutical, wellness, food and cosmetic applications.

In Europe, RAMM’s vertically integrated operations are described as being based in Ragusa, Italy and Elbląg, Poland. The group includes hemp cultivation platforms, large extraction and processing facilities, and, in earlier disclosures, two retail stores dedicated to the Marishanti cosmetic line. RAMM has stated that its strategic foothold in Europe provides distribution opportunities for its portfolio of registered cannabis-based products produced in Uruguay.

HemPoland and European hemp products

RAMM acquired all issued and outstanding shares of HemPoland Sp. z o.o., which it describes as a leading European manufacturer and marketer of premium hemp products. Company materials state that HemPoland is a licensed producer, contract manufacturer and distributor of hemp products, including CannabiGold-branded products and other white and private label products. Through this acquisition, RAMM gained access to HemPoland’s distribution network, premium brands and hemp oil extraction technologies, as well as an additional foothold in the European market.

Corporate structure and subsidiaries

Across its disclosures, RAMM lists several wholly owned subsidiaries that form part of its international platform. These include Canapar Corp., HemPoland Sp. z o.o., Medic Plast SA, Yurelan SA, Glediser SA, NettaLife (in connection with NettaVet™ products) and RAMM Pharma Holdings Corp. The exact subsidiary list varies slightly between news releases as acquisitions have been completed and operations expanded, but these entities are consistently presented as part of the RAMM group.

Strategic transactions and investments

RAMM has reported a number of corporate transactions that shape its business profile. The company initially acquired a significant stake in Canapar and later entered into a definitive acquisition agreement to acquire all remaining Canapar shares it did not already own, with the goal of integrating Canapar fully into its operations. RAMM has also announced the acquisition of HemPoland, which it describes as providing recognized brands, a distribution network and hemp oil extraction capabilities.

More recently, RAMM has disclosed a proposed investment transaction with The Global South S.A.S., a private Uruguayan simplified stock company and future issuer of the GSDC (Global South Digital Currency) stablecoin. The transaction, as described in company circular-related news, involves a proposed equity investment and a call option for additional ownership, subject to financing, definitive documentation, shareholder approvals and regulatory approvals. RAMM has explicitly stated that it does not currently have sufficient funds to complete this transaction and that there is no certainty regarding its completion.

Geographic footprint

Company communications consistently reference operations in Uruguay, Italy and Poland, with product authorizations in several Latin American countries. Uruguay is presented as the base for RAMM’s pharmaceutical and medical product business and its GMP-certified cannabis formulation facility. Italy and Poland are highlighted as European hubs for cultivation, extraction, processing and, in some disclosures, retail activities. Through these locations, RAMM positions its international production and sales platform across Latin American and European markets.

Stock information and industry classification

RAMM Pharma Corp. is listed on the Canadian Securities Exchange under the symbol RAMM and is also quoted over-the-counter as RAMMF. Based on the provided classification, the company is associated with the medicinal and botanical manufacturing industry within the broader manufacturing sector. Its disclosures emphasize cannabinoid pharmacology, cannabis-based pharmaceuticals, hemp-based products and vertically integrated cannabis and hemp operations.

Risk and forward-looking information

Company news releases include cautionary notes regarding forward-looking information. Statements about future regulatory approvals, expansion plans, transaction completion, market growth, or anticipated benefits of acquisitions and investments are characterized as forward-looking and subject to risks and uncertainties. Historical descriptions of RAMM’s approved products, existing facilities and completed acquisitions are presented as factual information, while future-oriented statements are identified as expectations or plans at the time of disclosure.